Huaixu Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Huaixu Li has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Hongqing Cai
Department of Neurosurgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
5 shared publications - Jinghai Wan
Department of Neurosurgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
5 shared publications - Yujia Chen
Department of Neurosurgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
4 shared publications - Qi Liu
Department of Neurosurgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
3 shared publications - Cheng Fang
Department of Neurosurgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
2 shared publications Chaoyong Zhang
Department of Neurosurgery, Taihe Hospital Affiliated to Wannan Medical College, Fuyang 236600, PR China
1 shared publication
Latest Publications
- Open Access
- 12 October 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (20) , 3316
Development and Temporal Validation of a Three-Metabolite Cerebrospinal Fluid Model for the Diagnosis of Leptomeningeal Metastasis from Solid Tumors
Background/Objectives: Leptomeningeal metastasis (LM) is a severe complication of solid tumors. Cerebrospinal fluid (CSF) cytology is only about 70% sensitive on a single examination, and objective markers are needed. Methods: CSF from 49 patients with LM and 16 with intracranial disease without LM was analyzed by targeted LC–MS in a training batch (n = 30) and a temporally independent validation batch (n = 35). Metabolites selected by both LASSO and random forest entered a logistic regression model, which was applied unchanged to the validation batch and evaluated by repeated and nested cross-validation on all 65 samples. Results: Hydroxyphenyllactic acid, argininosuccinic acid and norepinephrine were selected by both algorithms. The model reached an AUC of 0.954 in the training batch and 0.839 (95% CI 0.687–0.991) in the validation batch. In repeated cross-validation on all 65 samples, the AUC was 0.790 (95% CI 0.655–0.924), with sensitivity 0.714 and specificity 0.938; nested cross-validation gave 0.747. Conclusions: A three-metabolite CSF panel discriminates LM from non-LM and retains discrimination under cross-validation and in a temporally independent batch. It is a candidate adjunct to cytology and imaging whose specificity, based on 16 controls, requires confirmation in larger cohorts.
- 12 October 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (20) , 3316
Open AccessDevelopment and Temporal Validation of a Three-Metabolite Cerebrospinal Fluid Model for the Diagnosis of Leptomeningeal Metastasis from Solid Tumors
Background/Objectives: Leptomeningeal metastasis (LM) is a severe complication of solid tumors. Cerebrospinal fluid (CSF) cytology is only about 70% sensitive on a single examination, and objective markers are needed. Methods: CSF from 49 patients with LM and 16 with intracranial disease without LM was analyzed by targeted LC–MS in a training batch (n = 30) and a temporally independent validation batch (n = 35). Metabolites selected by both LASSO and random forest entered a logistic regression model, which was applied unchanged to the validation batch and evaluated by repeated and nested cross-validation on all 65 samples. Results: Hydroxyphenyllactic acid, argininosuccinic acid and norepinephrine were selected by both algorithms. The model reached an AUC of 0.954 in the training batch and 0.839 (95% CI 0.687–0.991) in the validation batch. In repeated cross-validation on all 65 samples, the AUC was 0.790 (95% CI 0.655–0.924), with sensitivity 0.714 and specificity 0.938; nested cross-validation gave 0.747. Conclusions: A three-metabolite CSF panel discriminates LM from non-LM and retains discrimination under cross-validation and in a temporally independent batch. It is a candidate adjunct to cytology and imaging whose specificity, based on 16 controls, requires confirmation in larger cohorts.
- Open Access
- 10 October 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (20) , 7827
The Efficacy and Safety of Adding Teniposide to Temozolomide Plus Bevacizumab in Recurrent Grade 4 Glioma: A Real-World Exploratory Single-Center Study
Background: Salvage options for recurrent grade 4 glioma (GBM) remain limited and no single standard of care has been established after recurrence. Teniposide (VM-26) has been reintroduced into clinical practice, but its benefit when added to temozolomide (TMZ) plus bevacizumab (Bev) in recurrent grade 4 glioma remains unclear. Methods: This single-center, real-world exploratory study retrospectively enrolled 53 patients with recurrent grade 4 glioma who received either teniposide plus TMZ and Bev (VM26 + TMZ + Bev, n = 26) or TMZ plus Bev (TMZ + Bev, n = 27). The control group combined patients treated before teniposide became available again in China (2020–2022) with those treated concurrently with the triplet (2023–2026). Safety was assessed using the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0; tumor response was evaluated according to the Response Assessment in Neuro-Oncology (RANO) criteria on an intention-to-treat basis, and survival was estimated by the Kaplan–Meier method. Results: Median progression-free survival (PFS) was 7.8 months (95% confidence interval (CI), 4.9–10.9) in the VM26 + TMZ + Bev group versus 5.1 months (95% CI, 4.4–6.8) in the TMZ + Bev group (log-rank p = 0.037; unadjusted hazard ratio (HR) 0.50, 95% CI, 0.25–0.97), and median overall survival (OS) was 12.7 months (95% CI, 8.4–15.4) versus 8.5 months (95% CI, 7.3–9.7) (log-rank p = 0.042; unadjusted HR 0.47, 95% CI, 0.23–0.98). Multivariable adjustment strengthened these estimates, whereas propensity score weighting and matching gave estimates of the same direction that did not reach significance. The objective response rate (ORR) was 26.9% (7/26) versus 14.8% (4/27) (p = 0.327) and the disease control rate (DCR) was 80.8% versus 77.8% (p = 1.000). Grade ≥ 3 adverse events (AEs) occurred in 11.5% versus 7.4% of patients (p = 0.669); leukopenia and neutropenia were more frequent with teniposide (26.9% vs. 3.7%; p = 0.024) but lost significance after Benjamini–Hochberg correction (q = 0.122). No unexpected toxicity types were observed, although any-grade leukopenia and neutropenia were more frequent with teniposide and should be anticipated in clinical use. Conclusions: In this exploratory real-world cohort, adding teniposide to TMZ plus Bev was associated with longer PFS and OS and a numerically higher ORR, without a significant increase in grade ≥ 3 toxicity, although any-grade leukopenia and neutropenia were more frequent and should be anticipated; however, treatment era could not be fully separated from treatment effect: in an era-matched analysis restricted to the concurrently treated cohorts, the direction of the effect was preserved but did not reach significance. The survival differences rested on a small number of events and were not robust to reclassification of individual patient outcomes. These findings warrant confirmation in prospective randomized studies.
- 10 October 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (20) , 7827
Open AccessThe Efficacy and Safety of Adding Teniposide to Temozolomide Plus Bevacizumab in Recurrent Grade 4 Glioma: A Real-World Exploratory Single-Center Study
Background: Salvage options for recurrent grade 4 glioma (GBM) remain limited and no single standard of care has been established after recurrence. Teniposide (VM-26) has been reintroduced into clinical practice, but its benefit when added to temozolomide (TMZ) plus bevacizumab (Bev) in recurrent grade 4 glioma remains unclear. Methods: This single-center, real-world exploratory study retrospectively enrolled 53 patients with recurrent grade 4 glioma who received either teniposide plus TMZ and Bev (VM26 + TMZ + Bev, n = 26) or TMZ plus Bev (TMZ + Bev, n = 27). The control group combined patients treated before teniposide became available again in China (2020–2022) with those treated concurrently with the triplet (2023–2026). Safety was assessed using the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0; tumor response was evaluated according to the Response Assessment in Neuro-Oncology (RANO) criteria on an intention-to-treat basis, and survival was estimated by the Kaplan–Meier method. Results: Median progression-free survival (PFS) was 7.8 months (95% confidence interval (CI), 4.9–10.9) in the VM26 + TMZ + Bev group versus 5.1 months (95% CI, 4.4–6.8) in the TMZ + Bev group (log-rank p = 0.037; unadjusted hazard ratio (HR) 0.50, 95% CI, 0.25–0.97), and median overall survival (OS) was 12.7 months (95% CI, 8.4–15.4) versus 8.5 months (95% CI, 7.3–9.7) (log-rank p = 0.042; unadjusted HR 0.47, 95% CI, 0.23–0.98). Multivariable adjustment strengthened these estimates, whereas propensity score weighting and matching gave estimates of the same direction that did not reach significance. The objective response rate (ORR) was 26.9% (7/26) versus 14.8% (4/27) (p = 0.327) and the disease control rate (DCR) was 80.8% versus 77.8% (p = 1.000). Grade ≥ 3 adverse events (AEs) occurred in 11.5% versus 7.4% of patients (p = 0.669); leukopenia and neutropenia were more frequent with teniposide (26.9% vs. 3.7%; p = 0.024) but lost significance after Benjamini–Hochberg correction (q = 0.122). No unexpected toxicity types were observed, although any-grade leukopenia and neutropenia were more frequent with teniposide and should be anticipated in clinical use. Conclusions: In this exploratory real-world cohort, adding teniposide to TMZ plus Bev was associated with longer PFS and OS and a numerically higher ORR, without a significant increase in grade ≥ 3 toxicity, although any-grade leukopenia and neutropenia were more frequent and should be anticipated; however, treatment era could not be fully separated from treatment effect: in an era-matched analysis restricted to the concurrently treated cohorts, the direction of the effect was preserved but did not reach significance. The survival differences rested on a small number of events and were not robust to reclassification of individual patient outcomes. These findings warrant confirmation in prospective randomized studies.
- Open Access
- 10 October 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (20) , 8984
TOP2A Overexpression as a Prognostic Biomarker in High-Grade Meningioma: An Integrated Single-Cell and Bulk Transcriptomic Study
While prior single-cell studies have identified proliferative neoplastic subpopulations, the prognostic and therapeutic implications of TOP2A focal copy-number status have not been defined. This study aimed to delineate the cellular architecture of high-grade meningioma and to evaluate the clinical and prognostic significance of TOP2A expression together with its focal copy-number status through integrated single-cell and bulk transcriptomic profiling. Single-cell RNA sequencing (scRNA-seq) was integrated with bulk RNA sequencing (bulk RNA-seq) to resolve the cellular landscape of high-grade meningioma in an exploratory cohort, followed by functional subcluster identification, differential expression analysis, and survival analyses. TOP2A was prioritized for multi-level validation: mRNA overexpression was confirmed in an independent bulk cohort, protein overexpression by immunohistochemistry (IHC), and focal gene copy-number status by fluorescence in situ hybridization (FISH). Kaplan–Meier survival analysis was performed to evaluate patient prognosis. Correlations between continuous variables were assessed using Spearman’s rank correlation coefficient. scRNA-seq of an exploratory high-grade cohort revealed a cell-cycle proliferation cluster characterized by high TOP2A expression. In a 160-sample bulk RNA-seq cohort, TOP2A was overexpressed in high-grade and recurrent tumors, and elevated TOP2A mRNA was significantly associated with shorter progression-free survival (PFS). IHC on 154 specimens confirmed TOP2A protein overexpression, and FISH on 27 specimens demonstrated focal TOP2A copy-number gain enriched in high-grade cases. Copy-number gain was concordant with TOP2A mRNA levels. Although TOP2A mRNA and protein overexpression were each associated with shorter PFS, the limited size of the FISH subset precluded an independent survival analysis by copy-number status. This study identifies TOP2A mRNA and protein overexpression as a prognostic biomarker in high-grade meningioma, and shows that focal TOP2A copy-number gain is enriched in high-grade tumors and concordant with TOP2A expression. By integrating transcriptional overexpression with copy-number gain, our findings identify TOP2A as a candidate prognostic biomarker warranting prospective evaluation in high-grade meningioma.
- 10 October 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (20) , 8984
Open AccessTOP2A Overexpression as a Prognostic Biomarker in High-Grade Meningioma: An Integrated Single-Cell and Bulk Transcriptomic Study
While prior single-cell studies have identified proliferative neoplastic subpopulations, the prognostic and therapeutic implications of TOP2A focal copy-number status have not been defined. This study aimed to delineate the cellular architecture of high-grade meningioma and to evaluate the clinical and prognostic significance of TOP2A expression together with its focal copy-number status through integrated single-cell and bulk transcriptomic profiling. Single-cell RNA sequencing (scRNA-seq) was integrated with bulk RNA sequencing (bulk RNA-seq) to resolve the cellular landscape of high-grade meningioma in an exploratory cohort, followed by functional subcluster identification, differential expression analysis, and survival analyses. TOP2A was prioritized for multi-level validation: mRNA overexpression was confirmed in an independent bulk cohort, protein overexpression by immunohistochemistry (IHC), and focal gene copy-number status by fluorescence in situ hybridization (FISH). Kaplan–Meier survival analysis was performed to evaluate patient prognosis. Correlations between continuous variables were assessed using Spearman’s rank correlation coefficient. scRNA-seq of an exploratory high-grade cohort revealed a cell-cycle proliferation cluster characterized by high TOP2A expression. In a 160-sample bulk RNA-seq cohort, TOP2A was overexpressed in high-grade and recurrent tumors, and elevated TOP2A mRNA was significantly associated with shorter progression-free survival (PFS). IHC on 154 specimens confirmed TOP2A protein overexpression, and FISH on 27 specimens demonstrated focal TOP2A copy-number gain enriched in high-grade cases. Copy-number gain was concordant with TOP2A mRNA levels. Although TOP2A mRNA and protein overexpression were each associated with shorter PFS, the limited size of the FISH subset precluded an independent survival analysis by copy-number status. This study identifies TOP2A mRNA and protein overexpression as a prognostic biomarker in high-grade meningioma, and shows that focal TOP2A copy-number gain is enriched in high-grade tumors and concordant with TOP2A expression. By integrating transcriptional overexpression with copy-number gain, our findings identify TOP2A as a candidate prognostic biomarker warranting prospective evaluation in high-grade meningioma.
- Open Access
- 10 October 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (20) , 7808
Ommaya Reservoir-Based Cerebrospinal Fluid Chemotherapy for Leptomeningeal Metastasis in the Era of Targeted Therapy: Safety, Survival, and Exploratory Prognostic Factors from a Single-Center Cohort
Objective: Real-world data on Ommaya reservoir-based cerebrospinal fluid (CSF) chemotherapy for leptomeningeal metastasis (LM) in the targeted-therapy era are limited. We describe its safety and survival and explore prognostic factors in lung adenocarcinoma-associated LM. Methods: We retrospectively reviewed 68 patients with LM treated with Ommaya reservoir implantation and CSF chemotherapy. Overall survival (OS) was estimated from LM diagnosis and from implantation, and an exploratory multivariable Cox regression was performed in patients with actionable driver mutations receiving targeted therapy. Results: Device-related complications occurred in six patients (8.8%), including three catheter malpositions after freehand placement; chemotherapy-related adverse effects occurred in four (5.9%). After a median follow-up of 12.8 months, 14 patients (20.6%) had died, 10 of CNS progression. Median OS was not reached from diagnosis (24-month OS 67.8%) and 18.7 months from implantation (24-month OS 48.3%). In the exploratory analysis (n = 46), KPS, age, and EGFR mutation subtype were associated with OS from both time origins. Conclusions: Ommaya reservoir-based CSF chemotherapy was feasible with few device-related complications. Because all patients were treated and most had lung adenocarcinoma receiving targeted therapy, the favorable survival cannot be attributed to the reservoir or generalized to other primary tumors; prognostic factors require prospective validation.
- 10 October 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (20) , 7808
Open AccessOmmaya Reservoir-Based Cerebrospinal Fluid Chemotherapy for Leptomeningeal Metastasis in the Era of Targeted Therapy: Safety, Survival, and Exploratory Prognostic Factors from a Single-Center Cohort
Objective: Real-world data on Ommaya reservoir-based cerebrospinal fluid (CSF) chemotherapy for leptomeningeal metastasis (LM) in the targeted-therapy era are limited. We describe its safety and survival and explore prognostic factors in lung adenocarcinoma-associated LM. Methods: We retrospectively reviewed 68 patients with LM treated with Ommaya reservoir implantation and CSF chemotherapy. Overall survival (OS) was estimated from LM diagnosis and from implantation, and an exploratory multivariable Cox regression was performed in patients with actionable driver mutations receiving targeted therapy. Results: Device-related complications occurred in six patients (8.8%), including three catheter malpositions after freehand placement; chemotherapy-related adverse effects occurred in four (5.9%). After a median follow-up of 12.8 months, 14 patients (20.6%) had died, 10 of CNS progression. Median OS was not reached from diagnosis (24-month OS 67.8%) and 18.7 months from implantation (24-month OS 48.3%). In the exploratory analysis (n = 46), KPS, age, and EGFR mutation subtype were associated with OS from both time origins. Conclusions: Ommaya reservoir-based CSF chemotherapy was feasible with few device-related complications. Because all patients were treated and most had lung adenocarcinoma receiving targeted therapy, the favorable survival cannot be attributed to the reservoir or generalized to other primary tumors; prognostic factors require prospective validation.
- 29 June 2026
- Published by Elsevier in Neuroscience
- Vol. 611, 85-98
Identification of polyamine metabolism-related gene signatures for prognostic and immunological stratification in glioma
- 29 June 2026
- Published by Elsevier in Neuroscience
- Vol. 611, 85-98
Identification of polyamine metabolism-related gene signatures for prognostic and immunological stratification in glioma
- Open Access
- 1 April 2025
- Published by SAGE Publications in Science Progress
- Vol. 108 (2)
Regulatory mechanisms of O6-methylguanine methyltransferase expression in glioma cells
O6-methylguanine methyltransferase (MGMT), a pivotal DNA repair enzyme, has its dysregulation playing a substantial role in gliomagenesis, the development of therapeutic resistance, and patient prognosis. This narrative review is designed to offer an all-encompassing overview of the intricate regulatory mechanisms that govern MGMT expression in glioma cells. We systematically investigate the diverse levels of regulation that impact MGMT expression in glioma. These include epigenetic regulation, transcriptional control, post-translational modifications, and the influence exerted by the tumor microenvironment. Epigenetically, methylation of CpG islands within the MGMT promoter region represents a critical determinant for gene silencing. Conversely, histone modifications such as H3K4me3 augment MGMT expression. Transcriptionally, a complex network of transcription factors, which encompasses Sp1, p53, and NF-κB, along with signaling pathways like TGF-β, JAK/STAT, and PI3K/AKT, orchestrates MGMT expression in glioma cells. Furthermore, post-translational modifications of MGMT, such as phosphorylation and ubiquitination, are of pivotal importance in modulating its stability and enzymatic activity. The tumor microenvironment, with factors such as oxidative stress, hypoxia, and immune responses, also exerts a significant influence on MGMT expression. This narrative review delves deeper into the relationship between MGMT expression and drug resistance, especially resistance to alkylating chemotherapy agents, and accentuates the significance of evaluating MGMT expression for personalized glioma therapy. By elucidating these regulatory mechanisms, this review endeavors to enhance our understanding of MGMT's role in glioma biology and to provide insights for future therapeutic strategies aimed at surmounting current treatment challenges.
- 1 April 2025
- Published by SAGE Publications in Science Progress
- Vol. 108 (2)
Open AccessRegulatory mechanisms of O6-methylguanine methyltransferase expression in glioma cells
O6-methylguanine methyltransferase (MGMT), a pivotal DNA repair enzyme, has its dysregulation playing a substantial role in gliomagenesis, the development of therapeutic resistance, and patient prognosis. This narrative review is designed to offer an all-encompassing overview of the intricate regulatory mechanisms that govern MGMT expression in glioma cells. We systematically investigate the diverse levels of regulation that impact MGMT expression in glioma. These include epigenetic regulation, transcriptional control, post-translational modifications, and the influence exerted by the tumor microenvironment. Epigenetically, methylation of CpG islands within the MGMT promoter region represents a critical determinant for gene silencing. Conversely, histone modifications such as H3K4me3 augment MGMT expression. Transcriptionally, a complex network of transcription factors, which encompasses Sp1, p53, and NF-κB, along with signaling pathways like TGF-β, JAK/STAT, and PI3K/AKT, orchestrates MGMT expression in glioma cells. Furthermore, post-translational modifications of MGMT, such as phosphorylation and ubiquitination, are of pivotal importance in modulating its stability and enzymatic activity. The tumor microenvironment, with factors such as oxidative stress, hypoxia, and immune responses, also exerts a significant influence on MGMT expression. This narrative review delves deeper into the relationship between MGMT expression and drug resistance, especially resistance to alkylating chemotherapy agents, and accentuates the significance of evaluating MGMT expression for personalized glioma therapy. By elucidating these regulatory mechanisms, this review endeavors to enhance our understanding of MGMT's role in glioma biology and to provide insights for future therapeutic strategies aimed at surmounting current treatment challenges.
- Open Access
- 1 January 2022
- Published by The Korean Brain Tumor Society, The Korean Society for Neuro-Oncology
- Vol. 10 (Suppl) , S265-1
Bioinformatics and network pharmacology-based strategy for predicting quercetin inhibits glioma proliferation by targeting CDK1 and CCNB1
Dai X, et al. Brain Tumor Res Treat. 2022 Mar;10(Suppl):S265-1. https://doi.org/10.14791/btrt.2022.10.F-2554
- 1 January 2022
- Published by The Korean Brain Tumor Society, The Korean Society for Neuro-Oncology
- Vol. 10 (Suppl) , S265-1
Open AccessBioinformatics and network pharmacology-based strategy for predicting quercetin inhibits glioma proliferation by targeting CDK1 and CCNB1
Dai X, et al. Brain Tumor Res Treat. 2022 Mar;10(Suppl):S265-1. https://doi.org/10.14791/btrt.2022.10.F-2554